



Amniotic Fluid Embolism

Amniotic Fluid Embolism (AFE)

A microscopic view of several red blood cells, which are biconcave discs, floating in a dark red fluid. The cells are illuminated from the side, creating a sense of depth and highlighting their characteristic shape.

- Rare and devastating
 - 1 in 20,000-30,000

Amniotic Fluid Embolism (AFE)

A microscopic view of several red blood cells, which are biconcave discs, scattered across a dark red background. The cells are rendered with a semi-transparent, glowing effect, highlighting their characteristic shape and color.

- Rare and devastating
 - 1 in 20,000-30,000
 - Mortality 25-80%

Amniotic Fluid Embolism (AFE)

A background image showing several red blood cells in a dark red, slightly blurred environment, suggesting a microscopic view of blood.

- Rare and devastating
 - 1 in 20,000-30,000
 - Mortality 25-80%
 - 12% of maternal deaths

Amniotic Fluid Embolism (AFE)

A background image showing several red blood cells in a microscopic view. The cells are biconcave and have a reddish-brown color. They are scattered across the frame, with some in sharp focus and others blurred in the background.

- Rare and devastating
 - 1 in 20,000-30,000
 - Mortality 25-80%
 - 12% of maternal deaths
 - 2/3 of deaths within 5 hours

Amniotic Fluid Embolism (AFE)

A microscopic view of several red blood cells, which are biconcave discs, scattered across the frame. The cells are rendered in a dark red color with a slight gradient, giving them a three-dimensional appearance. The background is a dark, almost black, color, which makes the red cells stand out prominently.

- Rare and devastating
 - 1 in 20,000-30,000
 - Mortality 25-80%
 - 12% of maternal deaths
 - 2/3 of deaths within 5 hours
 - 15-25% of survivors remain neurologically intact

(AFE) Clinical Presentation

- Not limited to the time of delivery
 - Occurs in all 3 trimesters and post-partum (8 ± 8 minutes following delivery)

(AFE) Clinical Presentation

- Not limited to the time of delivery
 - Occurs in all 3 trimesters and post-partum (8 ± 8 minutes following delivery)
- Seen during:
 - Vaginal or cesarean delivery
 - elective terminations
 - Amniocentesis
 - Amnioinfusion
 - blunt abdominal or surgical trauma

(AFE) Clinical Presentation

Signs or symptoms	Frequency
Hypotension	100%
Fetal distress	100%
Pulmonary edema or ARDS	93%
Cardiopulmonary arrest	87%
Cyanosis	83%
Coagulopathy	83%
Dyspnea	49%
Seizure	48%
Uterine atony	23%
Bronchospasm	15%
Transient hypertension	11%
Cough	7%
Headache	7%
Chest pain	2%

ARDS = adult respiratory distress syndrome.

Adapted from Clark SL, Hankins GD, Dudley DA, Dildy GA, Porter TF. Amniotic fluid embolism: analysis of the national registry. *Am J Obstet Gynecol* 1995;172:1158-67.

(AFE) Pathophysiology

- Embolic mechanism
 - Little correlation between presence of particulate matter in lung and severity of symptoms

(AFE) Pathophysiology

- Embolic mechanism
 - Little correlation between presence of particulate matter in lung and severity of symptoms
- Arachidonic acid metabolites (leukotrienes)

(AFE) Pathophysiology

- Embolic mechanism
 - Little correlation between presence of particulate matter in lung and severity of symptoms
- Arachidonic acid metabolites (leukotrienes)
- Immune mediated phenomenon with massive complement activation
 - “*anaphylactoid syndrome of pregnancy*”

(AFE) Pathophysiology

- Biphasic hemodynamic response
 - *Early phase:*
 - right sided failure due to pulmonary vasospasm
 - Less than 30 minutes

(AFE) Pathophysiology

- **Biphasic hemodynamic response**
 - *Early phase:*
 - right sided failure due to pulmonary vasospasm
 - Less than 30 minutes
 - *Second phase:*
 - Left ventricular failure
 - Pulmonary edema

(AFE) Pathophysiology

- Etiology of Coagulopathy
 - Amniotic fluid procoagulant (Factor X activator)

Lockwood CJ, Bach R, Guha A, Zhou XD, Miller WA, Nemerson Y. Amniotic fluid contains tissue factor, a potent initiator of coagulation. *Am J Obstet Gynecol* 1991;165:1335–41

(AFE) Pathophysiology

- Etiology of Coagulopathy
 - Amniotic fluid procoagulant (Factor X activator)
 - Amniotic fluid plasminogen activation inhibitor 1

(AFE) Pathophysiology

- Etiology of Coagulopathy
 - Amniotic fluid procoagulant (Factor X activator)
 - Amniotic fluid plasminogen activation inhibitor 1
- Circulating trophoblast

(AFE) Pathophysiology

- Etiology of Coagulopathy
 - Amniotic fluid procoagulant (Factor X activator)
 - Amniotic fluid plasminogen activation inhibitor 1
 - Circulating trophoblast
 - Simply massive hemorrhage due to uterine atony

Lockwood CJ, Bach R, Guha A, Zhou XD, Miller WA, Nemerson Y. Amniotic fluid contains tissue factor, a potent initiator of coagulation. Am J Obstet Gynecol 1991;165:1335-41

(AFE) Diagnosis

Table 2. Differential Diagnosis of Amniotic Fluid Embolism

Obstetric causes

- Acute hemorrhage
- Placental abruption
- Uterine rupture
- Uterine atony
- Eclampsia
- Peripartum cardiomyopathy

Anesthetic causes

- High spinal anesthesia
- Aspiration
- Local anesthetic toxicity

Nonobstetric causes

- Pulmonary embolism
 - Air embolism
 - Anaphylaxis
 - Sepsis/septic shock
-

Karetsky M, Ramirez M. Acute respiratory failure in pregnancy: an analysis of 19 cases. *Medicine (Baltimore)* 1998;77:41–9

(AFE) Diagnosis

- Diagnosis of exclusion
- Serum tryptase

Fineschi V, Gambassi R, Gherardi M, Turillazzi . The diagnosis of amniotic fluid embolism: an immunohistochemical study for the quantification of pulmonary mast cell tryptase. Int J Legal Med 1998;111:238-43

(AFE) Management

- OXYGENATION
- CIRCULATION
- COAGULATION
- DISPO

(AFE) Management

- OXYGENATION
 - Tracheal intubation (promptly)
 - 100% O₂
 - Positive pressure ventilation

(AFE) Management

- OXYGENATION
- CIRCULATION
 - Large bore intravenous access
 - Intra-arterial catheter
 - Pulmonary artery catheter
 - Vasopressor/Inotrope support
 - Volume support with crystalloid and colloid
 - Expeditious fetal delivery (if undelivered)

(AFE) Management

- OXYGENATION
- CIRCULATION (cont)
 - TEE monitoring?

RD, Iverson LI, Daugherty TM, Lovett SM, Terry C, Blumenstock E. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by trans-esophageal echocardiogram and treatment by cardiopulmonary bypass. *Obstet Gynecol* 2003;102:496–8

(AFE) Management

- OXYGENATION
- CIRCULATION (cont)
 - TEE monitoring?
 - Nitric oxide?

McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemodynamic compromise with nitric oxide in a patient with amniotic fluid embolism. *Int J Obstet Anesth* 2007;16:269–73

(AFE) Management

- OXYGENATION
- CIRCULATION (cont)
 - TEE monitoring?
 - Nitric oxide?
 - Cardiopulmonary bypass/ECMO

Hsieh YY, Chang CC, Li PC, Tsai HD, Tsai CH. Successful application of extracorporeal membrane oxygenation and intraaortic counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. Am J Obstet Gynecol 2000;183:496–7

(AFE) Management

- OXYGENATION
- CIRCULATION (cont)
 - TEE monitoring?
 - Nitric oxide?
 - Cardiopulmonary bypass/ECMO
- VAD

Nagarsheth NP, Pinney S, Bassily-Marcus A, Anyanwu A, Friedman L, Beilin Y. Successful placement of a right ventricular assist device for treatment of a presumed amniotic fluid embolism. *Anesth Analg* 2008;107:962–4

(AFE) Management

- OXYGENATION
- CIRCULATION
- COAGULATION
 - FFP, platelets, cryoprecipitate

(AFE) Management

- OXYGENATION
- CIRCULATION
- COAGULATION
 - FFP, platelets, cryoprecipitate
 - rFVIIa? Aprotinin?
 - Aminocaproic/tranexamic acid?

(AFE) Management

- OXYGENATION
- CIRCULATION
- COAGULATION
- DISPO
 - ICU management
 - Epidural catheter?